Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18

Fig. 3

a Frequency of neutropenia by grade during the first six cycles of treatment in the palbociclib plus letrozole arm of the study. b Frequency of Grade 3–4 neutropenia and all Grade infections during the first six cycles of treatment in the palbociclib plus letrozole arm of the study

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us